A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma. (23rd June 2017) - Pratt, Guy; Yap, Christina; Oldreive, Ceri; Slade, Daniel; Bishop, Rebecca; Griffiths, Mike; Dyer, Martin J. S.; Fegan, Chris; Oscier, David; Pettitt, Andrew; Matutes, Estella; Devereux, Stephen; et al.